ArticlemAbs2019

Half-life extension and non-human primate pharmacokinetic safety studies of i-body AD-114 targeting human CXCR4.

Katherine Griffiths et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.